WROCŁAW, Poland – November 19, 2025 – Captor Therapeutics S.A. (WSE: CTX), an innovative biopharmaceutical company, today announced it has entered into a Memorandum of Understanding with The University of Texas MD Anderson Cancer Center to support an Investigator-Initiated Trial (IIT) for Captor's lead asset – an MCL-1 protein degrader for the treatment of hematological malignancies.
The clinical trial builds upon preclinical research conducted at MD Anderson by Michael Andreeff, M.D., Ph.D., professor of Leukemia, and Bing Carter, Ph.D., professor of Leukemia, in collaboration with Captor. Amongst the findings, the clinical candidate, CT-03p, was shown to decrease MCL-1 protein levels, induce death of leukemia cells, and synergize with BCL-2 inhibition in cells resistant to venetoclax, CT-03p, or both. Updated results from this research will be presented at the American Society of Hematology Annual Meeting December 2025.
Abhishek Maiti, M.D., assistant professor of Leukemia at MD Anderson, will serve as the trial’s principal investigator.
